Iveda Solutions (IVDA) adds 2025 Form 10‑K; registers warrants and pre‑funded warrants

Rhea-AI Filing Summary

Iveda Solutions, Inc. files a Prospectus Supplement No. 14 dated April 1, 2026 that updates its August 30, 2022 prospectus to include the company’s Annual Report on Form 10-K for the period ended December 31, 2025 (filed March 31, 2026). The supplement covers registration language for 138,759 shares of common stock, warrants to purchase up to 411,185 shares of common stock at an exercise price of $11.20, and pre-funded warrants to purchase up to 273,685 shares of common stock, and incorporates the Form 10-K by reference.

The supplement is qualified by reference to the underlying prospectus and is intended to be read together with it, including its "Risk Factors" section. This document does not itself change offering terms; it adds the Form 10-K information to the existing prospectus package.

Insights

Securities Attorney

Supplement incorporates 2025 Form 10-K into the existing prospectus package.

The filing updates the August 30, 2022 prospectus by incorporating the Form 10-K for the period ended December 31, 2025, which is a common procedural step when offering documents rely on more recent financial disclosures.

Key qualifiers remain: the supplement is qualified by reference to the prospectus and refers investors to the "Risk Factors" section; no new offering mechanics or proceeds treatment are stated in this excerpt.

Capital Markets Analyst

Registers warrants and pre-funded warrants quantities without altering exercise terms disclosed earlier.

The supplement lists 138,759 shares, warrants for 411,185 shares at an exercise price of $11.20, and pre-funded warrants for 273,685 shares. These figures restate the securities subject to the prospectus framework.

Cashflow/issuer proceeds treatment is not stated in the excerpt; timing and distribution methods are those set in the underlying prospectus.

Key Figures

Prospectus Supplement date: April 1, 2026 Common stock listed: 138,759 shares Warrants: 411,185 shares +3 more

6 metrics

Prospectus Supplement date April 1, 2026 date of this Prospectus Supplement

Common stock listed 138,759 shares listed on the prospectus cover

Warrants 411,185 shares warrants to purchase up to 411,185 shares at $11.20 exercise price

Pre‑funded warrants 273,685 shares pre-funded warrants to purchase up to 273,685 shares

Form 10-K period end December 31, 2025 Annual Report period incorporated by reference

Form 10-K filed March 31, 2026 date the Form 10-K was filed with the SEC

Key Terms

Prospectus Supplement, pre-funded warrants, incorporated by reference, exercise price

4 terms

Prospectus Supplement regulatory

"This Prospectus Supplement supplements and amends the Prospectus dated August 23, 2022"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

pre-funded warrants financial

"Pre-Funded Warrants to Purchase up to 273,685 Shares of Common Stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

incorporated by reference regulatory

"filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Form 10-K”). The Form 10-K is attached hereto."

exercise price financial

"warrants to purchase 411,185 shares of common stock of Iveda Solutions, Inc. at an exercise price of $11.20"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Offering Details

resale/secondary

Offering

Offering Type resale/secondary

Prospectus Supplement No. 14	Filed Pursuant to Rule 424(b)(3)
(To Prospectus effective August 30, 2022)	Registration No. 333-267029

138,759 Shares of Common Stock

Warrants to Purchase up to 411,185 Shares of Common Stock

Pre-Funded Warrants to Purchase up to 273,685 Shares of Common Stock

This Prospectus Supplement supplements and amends the Prospectus dated August 23, 2022 and effective August 30, 2022 (the “Prospectus”), relating to the warrants to purchase 411,185 shares of common stock of Iveda Solutions, Inc. at an exercise price of $11.20 and pre-funded warrants to purchase 273,685 shares of common stock of Iveda Solutions, Inc. (the “Company”) by the stockholders identified in the Prospectus.

This Prospectus Supplement is being filed to include the information set forth in our Annual Report on Form 10-K for the period ended December 31, 2025, filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Form 10-K”). The Form 10-K is attached hereto.

This Prospectus Supplement is not complete without and may not be delivered or utilized except in connection with the Prospectus, including any supplements and amendments thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered with this Prospectus Supplement. This Prospectus Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Prospectus Supplement updates or supersedes the information contained in the Prospectus, including any supplements and amendments thereto.

See “Risk Factors” beginning on page 6 of the Prospectus to read about factors you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is April 1, 2026

FAQ

What does Iveda Solutions' Prospectus Supplement No. 14 do (IVDA)?

It incorporates the company’s Form 10-K for the period ended December 31, 2025 into the August 30, 2022 prospectus, updating disclosures and financial information for the registered securities.

How many warrants and pre‑funded warrants are covered in the supplement?

The supplement references warrants to purchase up to 411,185 shares and pre-funded warrants to purchase up to 273,685 shares, plus 138,759 shares of common stock listed in the cover language.

What is the exercise price for the warrants listed in IVDA’s supplement?

The warrants are stated to have an exercise price of $11.20 per share, as reflected in the prospectus language included in the supplement.

Does the prospectus supplement change the offering terms or proceeds usage?

No new offering mechanics or use‑of‑proceeds are specified in this excerpt; the supplement primarily incorporates the Form 10-K and defers to the underlying prospectus for terms.

When was the company’s Form 10-K filed that is incorporated by this supplement?

The Form 10-K for the period ended December 31, 2025 was filed with the SEC on March 31, 2026 and is attached to the prospectus supplement.